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patients with acute or sub-acute DVT with or without PTE without any signiﬁcant
complication.
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Background: Treatment of in-stent restenosis (ISR) of the femoropopliteal (FP) artery
remains a challenge to the endovascular specialist. Silverhawk (SA) and excimer laser
atherectomy (ELA) use different mechanisms in restenotic tissue reduction. We report
data on FP ISR treatment with SA and ELA in an unselected cohort of patients treated
at a single center.
Methods: Demographic, clinical, angiographic and procedural data was collected on
all patients that underwent SA and ELA (laser Elite 83.3%, Booster or Tandem
16.7%) for FP ISR from January 2005 until June 2010. Major adverse events and one-
year target lesion revascularization (TLR) were obtained by review of medical records
and phone calls. Univariate analysis was used to compare the 2 groups. Cox
Regression analysis for TLR over time was performed to adjust for differences
between the 2 cohorts and modeled for the following variables: SA vs. ELA, lesion
length, TASC D lesions (versus A-C), diabetes, age, gender and bail out stenting.
Results: 81 consecutive patients (41 SA, 40 ELA) were included in the analysis. ELA
was utilized more frequently in longer lesions, subacute presentation, TASC D
lesions, and in patients with more angiographic thrombus. Percent stenosis post ELA
was 56.6%  0.7% vs SA 33.8%  7.5% (p¼0.015). Percent stenosis post ELA was
56.6%  0.7% vs SA 33.8%  7.5% (p¼0.015). Final angiographic success (< 30%
residual narrowing post ﬁnal treatment) was similar between ELA and SA respectively
(92.5% vs. 100%, p¼0.12). Embolic ﬁlter protection was used equally in both
modalities (ELA 57.5% vs. SA 56.1%, p¼1.00). DE requiring treatment occurred in
2.5% in ELA vs 7.3% of SA (p¼0.2). There were no device related complications.
The primary outcome of TLR at 1 year occurred in 48.7% and 31.7% of ELA and SA
respectively (p¼0.171). ELA had a steeper failure rate than SA in the ﬁrst 6 months
post treatment and to a lesser extent after 6 months, whereas SA showed lesser TLR
initially but a higher TLR after 6 months. Cox Regression analysis showed that SA
was a predictor of TLR at 1 year.
Conclusions: Both SA and ELA continued to have high TLR rates in treating ISR of
the FP arteries. SA appears to be a predictor of TLR at 1 year.
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Background: Peripheral arterial disease (PAD) that results in critical limb
ischemia (CLI) is associated with signiﬁcant morbidity and mortality. Within the
ﬁrst year of diagnosis 25% of CLI patients will die and 30% will undergo
amputation. In this patient population that includes advanced age, diabetes, and renal
insufﬁciency, intra-arterial calcium is typically a predictor of poor endovascular
treatment success.
Methods: 3135 patients undergoing orbital atherectomy (OA) for treatment of PAD
were enrolled on an "all-comers" basis in 3 consecutive patient registries. All patients
were treated with the Orbital Atherectomy System manufactured by Cardiovascular
Systems, Inc. (St. Paul, MN). CONFIRM I evaluated the Diamondback360,
CONFIRM II evaluated the Predator360, and CONFIRM III evaluated Diamond-
back360, Predator360, and Stealth360. An analysis of the CLI data as it pertains to
the correlation of plaque morphology/calciﬁcation to the outcomes within the CLI
patient population after OA treatment was performed using the CONFIRM registry
series.
Results: 44% of the patients in the CONFIRM series had CLI (Rutherford
Categories 4-6) with documented lesion morphology, of which 87% presented with
moderate/severely calciﬁed lesions. There was no signiﬁcant difference in the
percentage of dissection (9.1% vs 12.2%), perforation (0.9% vs 0.6%), slow ﬂow
(5.7% vs 4.7%), closure (1.6% vs 1.2%), or spasm (6.4% vs 9.3%), in CLI
patients with moderate/severely calciﬁed lesions vs those without moderate/
severely calciﬁed lesions, respectively. Patients with CLI with moderate/severe
calcium had a lower rate of embolism (1.7% vs 5.2%, p¼0.01) and lower rate of
thrombus (0.9% vs 4.4%, p¼0.001) compared to patients without moderate/severely
calciﬁed lesions.
Conclusions: The majority of the CLI patients in this study had lesions with moderate
to severe calciﬁcation, yet the occurrence of adverse events was low after treatment
with orbital atherectomy. Orbital atherectomy is a safe tool for restoring blood ﬂow in
the lower extremities of CLI patients regardless of arterial calcium burden.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-541
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Background: Treatment of complex lesions in the femoropopliteal (FP) artery
including long, occluded, diffuse, thrombotic or calciﬁed lesions carries an increased
risk of major adverse events (MAE), reduced patency at 1 year and recurrent target
lesion revascularization (TLR). The post market multicenter JET registry is currently
evaluating the Jetstream atherectomy system in treating denovo or non stent restenotic
lesions of the FP artery.
Methods: JET is a multi-center, open-label, non-randomized registry in up to 75 sites
with a target enrolment of 500 patients, Rutherford category 1-3 and with denovo or non
stent restenotic FP lesions 4 cm in length and 70% in severity. Lesions with in-stent
restenosis, or crossed via a subintimal approach or treated within 1 month prior to index
procedure are excluded. The primary endpoint is binary stenosis at 12 months as deﬁned
by duplex ultrasound derived systolic velocity ratio>2.5. Secondary endpoints include
procedural success as deﬁned by successful revascularization of target vessel deﬁned as
 30% residual diameter stenosis following atherectomy  adjunctive therapy,
improvement in ankle-brachial index through 12 months compared to pre-procedural
baseline and MAE through 30 days. MAE is deﬁned as amputation, death, TLR, target
vessel revascularization, myocardial infarction, or angiographic distal embolization
requiring separate intervention or hospitalization. Index angiogram and duplex ultra-
sound assessment of binary stenosis will be evaluated by core laboratory.
Results: Preliminary results from the ﬁrst 60 patients enrolled in the JET registry are
as follows: mean age 65.5 yrs, males 68.3%, diabetics 50%, smoking history 63.4%,
hypertension 87.8%, Preprocedure ABI 0.68, non stent restenotic lesions 78.8%,
lesion length 174 mm, reference diameter 5.7 mm, pretreatment stenosis 90%, post
Jetstream stenosis 45% and post adjunctive treatment 9%. The JetStream total run was
3.52 min, adjunctive stenting was 30.9%. Distal embolic protection was used in only
3.6% of patients. There were no in-hospital complications.
Conclusions: Jetstream atherectomy of FP lesions appears to have a high procedural
success and reduced in-hospital complications.
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Background: The prognostic signiﬁcance of false lumen thrombus formation in type
B aortic dissection remains unclear.
Methods: Aortic dissection cases were identiﬁed from the Kaiser Permanente-
Registry of Aortic Dissections (KP-RAD). This is a population-based registry that
captures consecutive cases of aortic dissections among the approximately 3,000,000
health plan members in Southern California. The presence of any false lumen
thrombus by CT angiography during follow-up period was categorized as partial or
complete thrombus. The primary outcome was a composite of aorta related mortality,
myocardial infarction, stroke, aortic rupture, or dissection extension.
Results: There were 384 patients with type B aortic dissection, of which 293 had
a patent false lumen and 91 had partial or complete thrombosis. The mean age (SD)
for subjects with a patent false lumen was 69 (16) and 64 (13) with presence of false
lumen thrombus (p<0.001). There was no difference between groups for gender
(p¼0.20). The median follow up was 4 years with maximum follow-up of 7 years. The
cumulative incidence rate by presence or absence of false lumen thrombus was 30.0%
vs. 17.2% respectively (p¼0.01) (see ﬁgure).acts/POSTER/Endovascular Intervention B163
